PatientView Press Release: UK Patient Groups say that Pharma Should do More on Being Transparent

No Images?Click here

UK patient groups say that pharma should do more on being transparent

Embargoed publication date: Monday, 23rd April 2018 6AM GMT

Press release based on the results of a new report: 'The Corporate Reputation of Pharma, 2017—the Perspective of UK Patient Groups'

Contact details at end of email

  • This independent study, funded by PatientView, represents the perspectives of 83 UK-based patient groups on the corporate reputation of 15 individual pharma companies, and of the pharma industry as a whole, during 2017. The opinions of the UK patient groups, which were gathered in asurveyconducted November 2017-February 2018,are compared in the report with those from the entire worldwide body of 1,330 patient groups which responded to the PatientViewannual study,‘The Corporate Reputation of Pharma—from a Patient Perspective’,and with the UK patient-group responses fromthe previous year (2016).
  • The 15 pharma companies reviewed for their corporate reputation in the 2017 study are: AbbVieIAmgenIAstraZenecaIBayerIBoehringerIngelheimIBristol-Myers SquibbIEli Lilly (Lilly)IGSKIJanssenIMerck & Co (MSD in the UK)INovartisIPfizerIRocheISanofiITeva.
  • The UK corporate-reputation survey is now in its 6th edition—thus, 6 years of historical data are available. In addition,we incorporated several important new indicators of corporate reputation into the 2017 survey—to reflect the changing, and more demanding, relationships that now exist between patient groups and pharma companies.
  • The UK patient groups responding to the 2017surveyassessed the 15 companies for their excellence at:*patient centricity;*the provision of high-quality patient information;*patient safety;*the provision of high-quality products;*transparency (in pricing policies;in sharing the results of clinical data;and in the funding of external stakeholders);*integrity;*providing services 'beyond the pill';*engaging patients (in research, and indevelopment).

What UK patient groups say about pharma’s activities …

UK patient groups, like their peers inthe rest of the world, assessed thepharmaindustry'scorporate reputationas being slightly higher in 2017 than it was in 2016. However,only 28.6% of 2017's UK patient groups saw the industry's corporate reputation as "Excellent"or "Good", compared with 42.9% of the 1,330 patient groups worldwide. The 2017 results also indicatethat UK patient groups think thepharma industry still has a long way to go in corporate reputation.

Although UK patient groups rated the pharma industry as having a betteroverall corporate reputation in 2017, pharma was judgedlackingby those same UK patient groups in manyof its corporate activities. Mostnotablewas pharma's lack of transparency atsharingclinical data.

  • Just 8% of 2017's 83 UK patient groups thought pharma "Excellent" or"Good" at beingtransparentin the sharing of clinical data.

Results for individual pharmacompanies ...

AbbVieranked overall 1st in 2017 for corporate reputation among 15 pharma companies, according to the 23 respondent UK patient groups claiming familiarity with the company. UK patient groups also ranked AbbVie 1st in 2017 for three of the 12 indicators of corporate reputation used in the 2017 survey:*the provision of patient information;*high-quality products, useful to patients; and*transparency in its funding of external healthcare stakeholders.

The companies ranking top for each of 2017's 12 indicators of corporate reputation are shown in the accompanying table.

Onestriking finding is that no single company manages to excelin all indicators of corporate reputation. Instead, individual companies do well in, at most, one or several,indicators of corporate reputation.

In the case of transparency of clinical data,GSKranked top(probably due toits spearheadingof improvements in thearea).

Some companies saw a significant improvement in their results

Rising stars within the 2017 rankings among UK patient groups familiar with companies:

  • Bristol-Myers Squibbjumped nine places in the UK rankings—from overall 16th in 2016 (out of 17 companies), to overall 7th in 2017 (out of 15 companies). Noteworthy for 2017 were the significant increases in ranking that B-MS achieved forits patient-group partnerships, and forpatient centricity. B-MS ranked 3rd and 5th (respectively) in the UK for these two indicators in 2017. B-MS also ranked 1st in the UK in 2017 for transparency at pricing policies.
  • Novartisjumped seven places in the UK rankings—from overall 11th in 2016 (out of 17 companies), to overall 4th in 2017 (out of 15 companies). Novartis saw significant improvements in 2017 in its performance in the UK at many of the indicators of corporate reputation. The company ranked 1st in the UK in 2017 for the effectiveness of its patient-group partnerships—a fact echoed in Novartis’ Net Prometer Score (a standard measure of customer loyalty) of +55.6%. Novartis wasthe only company in2017's UK patient-group assessment to achieve a positive NPS measure.
  • Tevaalso jumped seven places in the UK rankings—from overall 15th in 2016 (out of 17 companies), to overall 8th in 2017 (out of 15 companies). UK patient groups familiar with the company marked Teva up in 2017 for several indicators of corporate reputation, placing the company in the higher tier of the UK league tables for four indicators of corporate reputation:*high-quality products;*transparency on pricing policies;*transparency on the sharing of clinical data; and*the provision of services ‘beyond the pill’.

-end of press release-

For more information on this new report,
'The Corporate Reputation of Pharma, 2017—from the Perspective of UK Patient Groups
CONTACT:
Alexandra Wyke
PatientView Ltd
Tel:++44-(0)1547-520-965
M:++44-(0)7432-660-796
Skype:Alex Wyke
e-mail:
Registered in England, number:3944382
Registered office:One Fleet Place, London, EC4M 7WS, UK

Like

Tweet

Forward